3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds
The Motley Fool
by newsfeedback@fool.com (Adria Cimino)February 23, 2026
AI-Generated Deep Dive Summary
Viking Therapeutics (NASDAQ: VKTX) is poised for significant growth if its obesity treatment pipeline proves successful in upcoming trials. The company’s lead candidate, VK2735, is currently in a phase 3 trial as an injectable drug and is expected to enter another phase 3 study in an oral format later this year. With the weight loss drug market booming—driven by high demand and blockbuster revenues for companies like Eli Lilly and Novo Nordisk—Viking Therapeutics stands out as a key player with potential to disrupt the industry.
The obesity treatment market is already a multi-billion dollar sector, and its growth shows no signs of slowing down. Viking’s injectable VK2735 has demonstrated promising results in earlier trials, targeting both weight loss and related metabolic conditions. If these trials succeed, the company could capture a significant share of this rapidly expanding market. Additionally, plans to test an oral version of the drug later this year could further broaden its potential appeal, offering patients a more convenient treatment option.
For investors, Viking Therapeutics represents a high-growth opportunity in a sector with proven demand. The company’s dual-pronged approach—injectable and oral formulations—positions it well to address different patient needs and preferences. With the obesity market expected to continue growing, Viking could emerge as a major player if its pipeline delivers on its potential. This makes Viking stock an intriguing option for those seeking high-reward
Verticals
financeinvesting
Originally published on The Motley Fool on 2/23/2026